From 1999 to 2017, there was a decrease in mortality among individuals with antineutrophil cytoplasmic autoantibody-associated vasculitides in the United States.
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare diseases that are generally specific to the lungs, kidneys and upper airways.
The study compared general and giant cell arteritis-specific characteristics in patients with and without visual symptoms, and examined the role of diagnostic delay in patients with giant cell arteritis experiencing current visual symptoms.
The FDA has approved Otezla (apremilast; Celgene) for the treatment of adult patients with oral ulcers associated with Behçet’s disease.
Researchers conducted a study to examine the frequency of VTEs in ANCA-associated vasculitis, and to identify its novel risk factors.
The incidence of infection increases with glucocorticoid dose for patients with polymyalgia rheumatica or giant cell arteritis.
The FDA has accepted for Priority Review the supplemental BLA for Rituxan for use in combination with glucocorticoids for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children ≥2 years old.
Researchers described the presentation, therapeutic management, and outcomes of ANCA-associated vasculitides-related orbital mass.
Researchers assessed the feasibility and construct validity of using PROMIS instruments in systemic vasculitis.
Researchers assessed the effect of AAV reclassification based on clinicopathologic criteria and ANCA specificity.